← All trials
NCT05566795
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2022
- Primary completion
- Dec 31, 2025
- Completion date
- Jan 31, 2030
- First posted
- Oct 4, 2022
- Last posted
- Oct 5, 2022
- Enrollment
- 400
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Day One Biopharmaceuticals, Inc.Lead sponsor
- SIOPe Brain Tumor Group LOGGIC ConsortiumCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.